Tuberc Respir Dis Search

CLOSE


Tuberc Respir Dis > Volume 66(3); 2009 > Article
Tuberculosis and Respiratory Diseases 2009;66(3):198-204.
DOI: https://doi.org/10.4046/trd.2009.66.3.198    Published online March 1, 2009.
Acquired Drug Resistance during Standardized Treatment with First-line Drugs in Patients with Multidrug-Resistant Tuberculosis.
Doosoo Jeon, , Dohyung Kim, , Hyungseok Kang, , Jinhong Min, , Nackmoon Sung, , Soohee Hwang, , Seungkew Park,
1National Masan Tuberculosis Hospital, Masan, Korea. sooli10kr@yahoo.co.kr
2International Tuberculosis Research Center, Masan, Korea.
Abstract
BACKGROUND
First-line drugs, if sensitive, are the most potent drugs in the treatment of multidrug-resistant tuberculosis (MDR-TB). This study examined the frequency and risk factors associated with acquired drug resistance to first-line drugs during a standardized treatment using first-line drugs in patients with MDR-TB. METHODS: This study included patients who were diagnosed with MDR-TB at the National Masan Tuberculosis Hospital between January 2004 and May 2008, treated with standardized first-line drugs, and for whom the preand post-treatment results of the drug susceptibility test were available. Their medical records were reviewed retrospectively. RESULTS: Of 41 MDR-TB patients, 14 (34.1%) acquired additional resistance to ethambutol (EMB) or pyrazinamide (PZA). Of 11 patients initially resistant to isoniazid (INH) and rifampicin (RFP), 3 (27.3%) acquired additional resistance to both EMB and PZA, and 3 (27.3%) to PZA. Of 18 patients initially resistant to INH, RFP and EMB, 6 (33.3%) acquired additional resistance to PZA. Of 6 patients initially resistant to INH, RFP and PZA, 2 (33.3%) acquired additional resistance to EMB. Ten of the 41 MDR-TB patients (24.4%) changed from resistant to susceptible. No statistically significant risk factors associated with acquired resistance could be found. CONCLUSION: First-line drugs should be used cautiously in the treatment of MDR-TB in Korea considering the potential acquisition of drug resistance.
Key Words: Tuberculosis, Multidrug resistance, Drug resistance


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2020 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2community

Close layer
prev next